Ocugen, Inc.
At Ocugen, we are focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, we are advancing vaccine research in the fight against COVID-19, and our work in cell therapy is aimed at orthopedic disease for which no effective treatment options currently exist.
NEWS
Looking for a biopharma job in Pennsylvania? Check out the BioSpace list of six companies hiring life sciences professionals like you.
A recent report by Tufts Medical Center reveals impressive approval rates for durable cell and gene therapies, but experts urge caution over persistent safety and accessibility concerns.
Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.
There’s a new collaboration in the Parkinson’s disease development space, Cardiff Oncology kicks off a mid-phase study in colorectal cancer and Ocugen published a new review of COVAXIN.
Homology Medicines and MiMedx both posted new CEOs. Other C-suite positions, including CFOs and CMOs were also filled this week.
The week began with positive updates in the vaccine development space against various infectious diseases from Emergent, Merck, Affinivax and Ocugen.
Ocugen introduced NeoCart, which is designed to repair full-thickness lesions of the knee cartilage in adults, as a Phase III cell therapy platform technology.
Lifting the clinical hold will allow Ocugen to continue to assess the vaccine in its ongoing study and potentially support its efforts to achieve EUA or full approval.
A roundup of last week’s top clinical trial updates and news.
JOBS
IN THE PRESS